These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies. Jang S; Atkins MB Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641 [TBL] [Abstract][Full Text] [Related]
3. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related]
4. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma. Kim A; Cohen MS Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499 [TBL] [Abstract][Full Text] [Related]
11. Dermatological adverse events from BRAF inhibitors: a growing problem. Belum VR; Fischer A; Choi JN; Lacouture ME Curr Oncol Rep; 2013 Jun; 15(3):249-59. PubMed ID: 23463215 [TBL] [Abstract][Full Text] [Related]
12. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient. Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693 [TBL] [Abstract][Full Text] [Related]
13. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma. Owen JL; Lopez IE; Desai SR J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671 [TBL] [Abstract][Full Text] [Related]
14. BRAF mutation testing algorithm for vemurafenib treatment in melanoma: recommendations from an expert panel. Gonzalez D; Fearfield L; Nathan P; Tanière P; Wallace A; Brown E; Harwood C; Marsden J; Whittaker S Br J Dermatol; 2013 Apr; 168(4):700-7. PubMed ID: 23360189 [TBL] [Abstract][Full Text] [Related]
15. Vemurafenib for the treatment of melanoma. Jordan EJ; Kelly CM Expert Opin Pharmacother; 2012 Dec; 13(17):2533-43. PubMed ID: 23094782 [TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304 [TBL] [Abstract][Full Text] [Related]
17. Targeting BRAF in melanoma: biological and clinical challenges. Mandalà M; Voit C Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641 [TBL] [Abstract][Full Text] [Related]
18. Molecularly targeted therapies for melanoma. Liu LS; Colegio OR Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367 [TBL] [Abstract][Full Text] [Related]
19. Vemurafenib: in unresectable or metastatic melanoma. Keating GM BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753 [TBL] [Abstract][Full Text] [Related]
20. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma. Seeley AR; De Los Santos JF; Conry RM Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]